Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with cardiorenal anemia syndrome.
Leszek
Przemysław
P
Kruszewski
Marcin
M
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004921:Erythropoietin / Q000627:therapeutic use*; D006333:Heart Failure / Q000097:blood / Q000150:complications / Q000503:physiopathology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000503:physiopathology*; D009200:Myocardial Contraction / Q000187:drug effects; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D011994:Recombinant Proteins; D013318:Stroke Volume / Q000187:drug effects; D013577:Syndrome; D013599:Systole; D016277:Ventricular Function, Left / Q000187:drug effects*; D020257:Ventricular Remodeling / Q000187:drug effects* / Q000502:physiology
D011994:Recombinant Proteins; D004921:Erythropoietin; D020097:Natriuretic Peptide, Brain